soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Heart disease is the #1 cause of death in type 2 diabetes — and for the first time, an GLP-1 drug has been proven to reduce major events The Oral Semaglutide's Impact on Cardiovascular
Description
Its predominant action is on the postprandial glucose levels, with extraglycemic effects on fat metabolism and endovascular function
As a scientist, its exciting to conduct research at this scaleusing millions of real-world data points to uncover measurable patterns and actionable insights
The study calls for urgent reform in peer review and greater transparency in scientific publishing.
There is growing evidence that Ozempic and other GLP-1 receptor agonist drugs might help people drink less alcohol, but more research is needed.
PlexusDx explains the evidence and how genetic testing helps personalize your approach
Although the reaction was sudden onset, it did not meet the Brighton Criteria of anaphylaxis
